Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

teva_copy

Teva announces FDA approval for asthma injection, Cinqair

March 24, 2016 Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair

The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …
News

Biotech Micreos appoints CMO to lead clinical development of antibiotic alternative

March 23, 2016 Research and Development

Dr Johan Frieling has been appointed as the new chief medical officer of Dutch biotech company Micreos, at a pivotal …
Appointment
sanofi_pasteur_scientist

Sanofi and Regeneron meet endpoint in Phase III Praluent study

March 23, 2016 Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial

Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
News
bms_good

Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m

March 23, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis

Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …
News
brilinta

AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients

March 23, 2016 Research and Development AstraZeneca, Brilinta, stroke

AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …
News
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016 Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
News
eli_lilly

FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016 Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …
News
fda_sign_web

FDA announces strongest warnings for opioid pain medications

March 23, 2016 Medical Communications, Research and Development FDA, abuse, addiction, boxed, label, misuse, opioids, public health, restrictions, safety, warnings

The US Food and Drug Administration has announced class-wide safety labelling changes for immediate release (IR) opioid pain medications. The …
News
nice

NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi

March 23, 2016 Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis

NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …
News
jose_conejo-garcia_-_wistar_institute

Targeted cancer therapies can suppress T cell immune responses, study finds

March 23, 2016 Research and Development T cell, anti-cancer drugs, immunosuppresive, superagonist, wistar institute

Researchers at the Wistar Institute have developed a new method whereby targeted cancer therapies can provide appropriate therapeutics without supressing …
News
shutterstock_141299494

Celyad teams-up with Institut Curie to advance its immuno-oncology program

March 22, 2016 Manufacturing and Production, Research and Development Cancer Immunotherapy, Celyad, Institut Curie, cellular immunotherapies

Celyad (Nasdaq: CYAD) on Tuesday said it has partnered with Institut Curie to develop its NKR-T pipeline in cellular immunotherapies …
News
2174264_eisai_logo

Eisai withdraws application for neurodegenerative-disease drug in Japan

March 22, 2016 Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease

Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …
News

BioMarin reports mixed Phase III results for genetic disorder trial-drug Pegvaliase

March 22, 2016 Manufacturing and Production, Research and Development

Biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) reported mixed results for its trial drug to treat genetic disorder phenylketonuria. Trial drug, …
News
cancer_cells

Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours

March 22, 2016 Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …
News

Raptor’s Procysbi gets Priority Review from Health Canada

March 22, 2016 Manufacturing and Production, Research and Development Canada, Health Canada, Procysbi, Raptor Pharmaceutical, genetic condition

Raptor Pharmaceutical (Nasdaq: RPTP) said Canadian regulators have accepted a priority review for its drug to treat a rare genetic …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025